Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects

Group 1 - Kalvista Pharmaceuticals Inc. is recognized as a promising investment opportunity, particularly due to its growth trajectory linked to the successful launch of EKTERLY, an oral therapy for hereditary angioedema (HAE) [2][3] - The company has achieved significant market penetration with EKTERLY, having 937 start forms that cover approximately 8% of diagnosed HAE patients in the US, translating to a potential revenue of about $31 million [2] - Kalvista reported $13.7 million in net product revenue during the third quarter and ended the quarter with $309.2 million in cash and cash equivalents, indicating a strong financial position to support future growth [3] Group 2 - The company has received regulatory approvals for EKTERLY in five regions, including Germany and Australia, showcasing its expanding market presence [3][4] - Kalvista focuses on developing oral therapies for rare diseases, specifically targeting the plasma kallikrein enzyme, which is crucial in the pathophysiology of HAE attacks [4]